AstraZeneca’s candidate hypertension drug baxdrostat demonstrated approximately 10 mmHg blood pressure reductions in a pivotal phase 3 trial, setting the stage for imminent FDA submission. The success follows comprehensive clinical evaluation highlighting its efficacy in lowering blood pressure in patients with hypertension. This advancement positions baxdrostat as a promising addition to the cardiovascular therapeutic arsenal.